You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Hypnosedative prescribing in outpatient psychiatry

Huthwaite, Mark A.a; Andersson, Viktoriac; Stanley, Jamesb; Romans, Sarah E.a

International Clinical Psychopharmacology:
doi: 10.1097/YIC.0b013e32836248f1
Original Articles

The objective of this study was to describe hypnosedative (HS) prescribing patterns in a typical sample of psychiatric outpatients. Prescription information was extracted from the clinical records of all current outpatients at two New Zealand public mental health centres. This included the type and duration of HS use and documentation of a clinical review of longstanding (>3 months) use, patient sex, age and ICD10 diagnoses. One-third of the patients (35.2%) were prescribed at least one HS; this was longstanding in two-thirds (69%). One in 10 had a coprescription of more than one HS drug. HS use was related to female sex and diagnosis, being more common among patients with nonpsychotic than psychotic disorders and very infrequent in patients on clozapine. In most longstanding cases, a clinical review had been documented. The logistic regression confirmed female sex, diagnosis and clozapine all as independent predictors of HS prescription. HS prescribing in psychiatric illness is more common than in the general population, often longstanding, with polypharmacy being common. The frequent use of antipsychotic drugs as HSs is of concern, given their side-effect profile. As there are risks involved with longstanding HS use, a better rationale for the role of medication in the management of sleep problems in psychiatric disorders is needed.

Author Information

Departments of aPsychological Medicine

bPublic Health, University of Otago Wellington, Wellington, New Zealand

cKarolinska Institute, Stockholm, Sweden

Correspondence to Sarah E. Romans, MD, MB, Department of Psychological Medicine, University of Otago Wellington, PO Box 7343, Wellington 6242, New Zealand Tel: +64 4 385 5541 x6584; fax: +64 4 385 5877; e-mail:

Received January 31, 2013

Accepted April 16, 2013

© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins